ACROBAT: The effect of early cryoprecipitate transfusion versus standard care in women who develop severe postpartum haemorrhage: A pilot cluster randomised trial.
Cryoprecipitate transfusion has been part of standard treatment for management of women who develop severe post-partum haemorrhage (PPH) in the UK for over 40 years. However, the timing when it should be introduced during the course of PPH has not been studied. Our hypothesis is that by giving cryoprecipitate earlier, we may improve fibrinogen levels and potentially stop bleeding quicker, compared to standard care where cryoprecipitate is administered later in the course of bleeding. Before proving this in a large randomised trial, we will need to test whether it is feasible to deliver different components of the trial in this feasibility study.
A pilot study to assess the feasibility of early administration of cryoprecipitate, recruitment of participants and collection of outcome data, alongside a qualitative evaluation.
Study start: 1st March 2019
Study Duration: 12 Months
Recruitment Target: 200
Chief Investigator: Dr. Laura Green
Trial Contact Details:
ACROBAT Trial Coordinator
Barts Centre for Women’s Health
Institute of Population Health Sciences
Barts and The London School of Medicine & Dentistry
Queen Mary University of London
Yvonne Carter Building
58 Turner Street, London E1 2AB
Tel: +44 (0)20 7882 6694